XTL Biopharmaceuticals, Ltd. Announces Managerial Change
July 06 2006 - 6:58AM
PR Newswire (US)
NEW YORK, July 6 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals,
Ltd. (NASDAQ:XTLBNASDAQ:LSE:NASDAQ:XTLNASDAQ:TASE:NASDAQ:XTL) today
announced that as part of the on-going process to consolidate key
managerial positions, Mr. Jonathan Burgin, Chief Financial Officer,
will depart the Company effective today. Bill Kessler, the
Company's Finance Director, will become Principal Financial and
Accounting Officer for financial and compliance reporting purposes.
Commenting on Mr. Burgin's departure, Ron Bentsur, XTLbio's Chief
Executive Officer, said, "Jonathan is a consummate professional and
on behalf of the Company, I want to thank him for 7 years of
dedicated service to XTLbio. I wish him much success in his future
endeavors." About XTL Biopharmaceuticals, Ltd. XTL
Biopharmaceuticals Ltd. ("XTLbio") is engaged in the acquisition,
development and commercialization of therapeutics for the treatment
of infectious diseases, with a focus on hepatitis C. XTLbio is
developing XTL-2125 - a small molecule, non-nucleoside inhibitor of
the hepatitis C virus polymerase - presently in Phase 1 clinical
trials in patients with chronic hepatitis C. XTLbio is also
developing XTL-6865 - a combination of two monoclonal antibodies
against the hepatitis C virus - presently in Phase 1 clinical
trials in patients with chronic hepatitis C. XTLbio's hepatitis C
pipeline also includes several families of pre-clinical hepatitis C
small molecule inhibitors. In addition, XTLbio has out-licensed to
Cubist Pharmaceuticals an antibody therapeutic against hepatitis B,
HepeX-B, which has recently completed a Phase 2b clinical study in
hepatitis B liver transplant patients. XTLbio is publicly traded on
the Nasdaq, London, and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(LSE:XTL)(TASE:XTL). Contact: Ron Bentsur Chief
Executive Officer +1-(212)-531-5971 DATASOURCE: XTL
Biopharmaceuticals Ltd CONTACT: Ron Bentsur, Chief Executive
Officer, +1-(212)-531-5971,
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024